Skip to main content
. 2022 Jun 3;39(10):2405–2419. doi: 10.1007/s11095-022-03305-y

Table II.

Summary pharmacokinetic parameters for tolfenamic acid in plasma after oral gavage of suspension and lipid-based formulations (MCF-2) of tolfenamic acid and a lipid-based formulation (MCF-2) of Tol Dec Ala ionic liquid

Compound Formulation Dose
(mg/kg Tol equivalents)		 Tmax (h) Cmax (µg/mL) AUC (0-15 h) (µg/mL.h) AUC (0-15 h) (µg/mL.h) normalised*
Tolfenamic acid Suspension 18.7 1.19 ± 0.88 5.3 ± 1.9 27.2 ± 6.85 27.2 ± 6.85
Tolfenamic acid LBF (MCF-2) 18.7 0.33 ± 0.14 20.6 ± 6.0 30.5 ± 9.82 30.5 ± 9.82
Tol Dec Ala IL LBF (MCF-2) 87.7 0.33 ± 0.13 21.7 ± 11 95.5 ± 46.1 38.8 ± 18.7

* Data normalised to a nominal dose of 18.7 mg/kg Tol to provide dose normalised exposure comparison.